Neurol. praxi. 2016;17(5):333-334

Je třeba léčit demenci u Parkinsonovy nemoci?

MUDr. Martin Nevrlý, Ph.D.1, prof. MUDr. Ján Benetin, CSc.2
1 Neurologická klinika, FN a LF UP v Olomouci
2 II. neurologická klinika LF UK SZU a UNB, Bratislava

Published: November 7, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Nevrlý M, Benetin J. Je třeba léčit demenci u Parkinsonovy nemoci? Neurol. praxi. 2016;17(5):333-334.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-S?rensen P. Prevalence and characte - ristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003; 60(3): 387-392. Go to original source... Go to PubMed...
    2. Braak H, Ru?b U, Jansen Steur EN, Del Tredici K, de Vos RA. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 2005; 64(8): 1404-1410. Go to original source... Go to PubMed...
    3. Brennan L, Pantelyat A, Duda JE, Morley JF, Weintraub D, Wilkinson JR, Moberg PJ. Memantine and cognition in Parkinson's disease dementia/dementia with Lewy bodies: A meta-analysis. Movement Disorders. 2016; 3: 161-167. Go to original source... Go to PubMed...
    4. Litvan I, Goldman JG, Tröster A I, Schmand BA, Weintraub D, Petersen RC, Mollenhauer B, Adler CH, Marder K, Williams-Gray CH, Aarsland D, Kulisevsky J, Rodriguez-Oroz MC, Burn DJ, Barker RA, Emre M. Diagnostic criteria for mild cognitive impairment in Park-inson's disease: movement Disorder Society Task Force guidelines. Movement Disorders. 2012; 27(3): 349-356. Go to original source... Go to PubMed...
    5. Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bod-ies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev. 2012; 3: CD006504. Go to original source... Go to PubMed...
    6. ##
    7. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003; 60: 387-392. Go to original source... Go to PubMed...
    8. Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson's disease. Brain Pathol. 2010; 20: 633-639. Go to original source...
    9. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol. 2003; 2: 229-237. Go to original source... Go to PubMed...
    10. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, RosaMM, Wolters E, Quarg P, Tekin S, Lane R. Rivastigmin for Dementia Associated with Parkinson's Disease. N Engl J Med. 2004; 351: 2509-2518. Go to original source... Go to PubMed...
    11. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J,Dickson DW, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R, LitvanI, McKeith I, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, Dubois B. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord. 2007; 22: 1689-1707. Go to original source... Go to PubMed...
    12. Parkinson J. An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci. 2002; 14: 223-236.
    13. Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner EM, Poewe W, Rascol O, Goetz CG, Sampaio C. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the Non-Motor Symptoms of Parkinson's Disease. Mov Disord. 2011; 26: S42-S80. Go to original source... Go to PubMed...
    14. Tiraboschi P, Hansen LA, Alford M, Sabbagh MN, Schoos B, Masliah E, Thal LJ, Corey-Bloom J. Cholinergic dysfunction in diseases with Lewy bodies. Neurology. 2000; 54: 407-411. Go to original source... Go to PubMed...
    15. Verbaan D, Marinus J, Visser M, van Rooden SM, Stiggelbout AM, Middelkoop HA, van Hilten JJ. Cognitive impairment in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2007; 78: 1182-1187. Go to original source... Go to PubMed...
    16. Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain. 2007; 130: 1787-1798. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.